**Name of Journal:** *World Journal of Radiology*

**Manuscript NO:** 82425

**Manuscript Type:** REVIEW

**Hepatocellular carcinoma: State of the art diagnostic imaging**

Criss C *et al*. Hepatocellular carcinoma imaging

Cody Criss, Arpit M Nagar, Mina S Makary

**Cody Criss,** Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, United States

**Arpit M Nagar, Mina S Makary,** Department of Radiology, The Ohio State University Medical Center, Columbus, OH 43210, United States

**Author contributions:** Cody C designed and wrote the review; Nagar AM reviewed and critically advised the paper; Makary MS supervised and critically revised the paper.

**Corresponding author: Mina S Makary, MD, Assistant Professor, Attending Doctor, Director,** Department of Radiology, The Ohio State University Medical Center, 395 W. 12th Ave., Columbus, OH 43210, United States. mina.makary@osumc.edu

**Received:** December 18, 2022

**Revised:** February 12, 2023

**Accepted:** March 22, 2023

**Published online:** March 28, 2023

**Abstract**

Primary liver cancer is the fourth most common malignancy worldwide, with hepatocellular carcinoma (HCC) comprising up to 90% of cases. Imaging is a staple for surveillance and diagnostic criteria for HCC in current guidelines. Because early diagnosis can impact treatment approaches, utilizing new imaging methods and protocols to aid in differentiation and tumor grading provides a unique opportunity to drastically impact patient prognosis. Within this review manuscript, we provide an overview of imaging modalities used to screen and evaluate HCC. We also briefly discuss emerging uses of new imaging techniques that offer the potential for improving current paradigms for HCC characterization, management, and treatment monitoring.

**Key Words:** Hepatocellular carcinoma; Imaging; Diagnostic; Magnetic resonance imaging; Computed tomography; Ultrasound; Radiogenomics

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Criss C, Nagar AM, Makary MS. Hepatocellular carcinoma: State of the art diagnostic imaging. *World J Radiol* 2023; 15(3): 56-68

**URL**: https://www.wjgnet.com/1949-8470/full/v15/i3/56.htm

**DOI**: https://dx.doi.org/10.4329/wjr.v15.i3.56

**Core Tip:** Successful tumor assessment can be a critical component to patient management and prognosis. The expansion of imaging techniques beyond conventional modalities (*e.g.* ultrasound, computed tomography, magnetic resonance imaging) provides an opportunity to improve the identification of small or well-differentiated hepatocellular carcinoma tumors, along with the capability to monitor treatment responses to surgery or locoregional therapy.

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is the most common liver malignancy, accounting for 90% of liver tumors, and a leading cause of mortality worldwide[1,2]. Global risk factors for HCC include cirrhosis, existing in up to 90% of new cases[3], or patients with long-standing liver infections such as viral hepatitis B and C[4]. East Asia and sub-Saharan Africa account for greater than 80% of cases, and incidence within the United States continues to rise[3,4]. Unfortunately, many patients are diagnosed in the advanced stages of the disease, which emphasizes the importance of early detection and surveillance[5]. Surveillance and early tumor detection using ultrasonography is recommended by the American Association for the study of Liver Diseases (AASLD) for high-risk populations driven by ultrasound-guided imaging. Unlike other malignancies, HCC expresses distinctive characteristics that can be diagnosed based on imaging features alone, without the need for confirmation from tissue sampling[6]. In this review, we provide a summary of diagnostic criteria and imaging modalities used to detect and stage HCC, as well as emerging methods to further assist in the surveillance and characterization of the disease.

**SURVEILLANCE AND SCREENING**

***Conventional ultrasound***

Tumor burden can significantly impact management, where patients with small, localized tumors can receive curative methods such as liver transplantation, resection, or locoregional therapies. On the other hand, treatment options are limited in patients with HCC displaying more aggressive features (*e.g.*, extrahepatic metastases, multifocal tumors, and vascular invasion). As a result, early detection may offer a significant benefit in select patients. Patient populations recommended for HCC surveillance differs between AASLD[7], the European Association for the Study of the Liver (EASL)[8] and the Asian Pacific Association for the Study of the Liver (APASL)[9], but largely consist of adults with cirrhosis or patients with hepatitis B virus (HBV)[10]. Across surveillance recommendations, biannual abdominal ultrasonography (Figure 1) is the standard modality for HCC detection with major advantages including accessibility, cost-effectiveness, and safety[10].

Surveillance programs typically consist of ultrasound examination performed at either 6- or 12-mo intervals. Across all stages of HCC, ultrasound detection carries 84% sensitivity. A number of investigations have found a mortality and cost-benefit of biannual ultrasonography for imaging surveillance of HCC[10–12]. For example, a study in HBV-infected patients in China found a 37% reduction in mortality in those receiving biannual ultrasonography examinations compared to the control group[12]. Suboptimal visualization poses a major limitation for ultrasound screening. Poor visualization and sonographic sensitivity to HCC lesions can be caused by a number of different extrinsic factors such as morbid obesity, patient inability to suspend respiration, obscured portions of the liver by bowel gas or rib shadowing, and intrinsic factors such as hepatic steatosis or fibrosis causing parenchymal heterogenicity[13]. A recent investigation reported approximately 20% of scans were inadequate to exclude liver lesions[14]. Detecting smaller nodules (< 2 cm) appears to be a major limitation of ultrasound, with studies reporting detection rates as low as approximately 28%[15]. In response, the American College of Radiology (ACR) screening guidelines have recommended the use of systematic documentation and scoring for visualization (A: No or minimal limitations; B: Moderate limitations; C: Severe limitations). The use of tumor biomarkers, such as alpha-fetoprotein (AFP), in concert with ultrasound examination appears to have an additive effect on detection rate[16]. For example, a recent meta-analysis of prospective studies found the sensitivity for ultrasound alone to detect any stage of HCC was 78% compared to 97% when adding AFP[17]. Interestingly, the synergistic impact of combining ultrasound with AFP also exists for detection of earlier, smaller nodules (45% *vs* 63% sensitivity, respectively)[17] which is particularly salient given the limitations of ultrasound and earlier stages of HCC. This is not without controversy, however. The 2018 AASLD guidelines do not designate any preferences between adjunctive use of AFP while the 2017 APASL guidelines recommend the combination of ultrasound and AFP[18]. In contrast, the 2018 EASL guidelines discourage the use of ultrasound with AFP for 6-mo HCC surveillance, citing concerns of false-positives in the setting of active liver inflammation with infection[18].

While the objective of this review is to elucidate the latest advancements in technological imaging for the screening and diagnosis of HCC, it is important to note the efficacy of detection can be limited due to multifactorial screening challenges. In fact, less than 1 in 5 patients with cirrhosis receive surveillance screening for HCC[19]. Previous reviews have extensively examined the numerous challenges encountered during the screening process, including the inability to properly stratify high-risk patients, the presence of socio-economic and logistical impediments to accessing healthcare, as well as training and detection limitations using conventional imaging techniques, as previously discussed. One of the most common attributable factors to surveillance underuse includes lack of surveillance orders or unrecognized cirrhosis[5]. Therefore, strategies to improve education and integrating primary care providers in surveillance efforts can have a drastic and meaningful effect on rates of patients undergoing HCC screening[20]. The implementation of patient-centered outreach programs such as reminder protocols or embedding best-practice advisories within the electronic health record may be solutions to improve barriers of patients undergoing surveillance[5,20]. The decision to select which patients to screen also been discussed and studies have developed scoring systems across different risk factors (*e.g.* hepatitis or cirrhosis) to refine and improve risk stratification have been proposed[21]. Other methods have also focused on improving surveillance outcomes and detection rates, such as utilizing serological biomarkers (*e.g.* AFP) either as a single screening modality or in concert with imaging to improve sensitivity, at the potential cost of increased rates of false positivity. The use of biomarkers may also be especially helpful for smaller HCCs, not easily visible with ultrasound[21].

**HCC DIAGNOSTIC MODALITIES**

***Liver imaging reporting and data systems diagnostic reporting system***

Established by the ACR, standardized methods for imaging interpretation and reporting are defined using the liver imaging reporting and data systems (LI-RADS). The application of the LI-RADS diagnostic algorithm was initially developed for computed tomography (CT)/magnetic resonance imaging (MRI). LI-RADS is subdivided into 8 categories and ranges in greater probability of malignancy from LR-1 to LR-5 with additional categories including LI-RADS M (LR-M) (probably or definitely malignant but not HCC specific), LR-definite tumor in vein, and LR-cannot be categorized (NC)[13,22]. Observation of lesions categorized in LR-5 is designated as almost certainly HCC, with a systematic review of 454 studies reporting 94% of LR-5 lesions confirmed to be HCC and 97% malignant[23]. The Organ Procurement and Transplantation Network (OPTN) is another diagnostic criterion established by National Organ Transplant Act, with subcategories ranging from class 0-5. Specificities are similar between LI-RADSv2018 LR-5 and OPTN class 5[24]. However, inter-reader agreement and sensitivity of LI-RADS (sensitivity: 63.9%) is higher than that of OPTN (sensitivity: 53.6%)[24].

***Cross-sectional imaging: Multiphase CT and MRI***

Standard recommendations for HCC diagnosis include multiphase CT or MRI which are beneficial modalities for highlighting unique features of HCC (Figures 2 and 3). Physiological differences in blood perfusion between hepatocarcinogenic lesions and non-neoplastic tissue display distinguishing differences in imaging characteristics using multiphasic contrast examinations[25]. Phases consist of late hepatic arterial (20-40 s), portal venous (60-90 s), and delayed (3-5 min). Late arterial phase is useful for detecting hypervascular lesions with HCC lesions characteristically enhancing relative to surrounding liver parenchyma. Arterial lesion enhancement can be appreciated within lesions as small as 1 cm. Within the portal venous and delayed phases, washout or hypointensity is commonly observed for HCC lesions[26]. During the delayed or equilibrium phase, other characteristics of HCC such as capsule features (*e.g.* lesion washout with pseudocapsule enhancement) and mosaic architecture can be visualized[26]. The introduction of gadolinium-based contrast agents (Gadobenate dimeglumine and gadoxetate acid) may aid LI-RADS categorization. These agents are taken up by hepatocytes of normal liver parenchyma and there is little uptake in non-functioning or dysfunctional hepatocytes, such as the case for HCC. Gadolinium-based agents function similarly to extracellular agents, but can aid in the diagnosis of lesions with atypical features (*e.g.* without washout, arterial hyperenhancement) or distinguish HCC from pseudolesions[27,28]. For example, these agents permit an additional post-contrast hepatobiliary phase, which will display a majority of HCC lesions (90%-95%) as hypointense relative to surrounding hyperintense liver parenchyma[27,29].

MRI is recommended for staging of HCC disease given that some reports have estimated CT to underestimate 52% of cases[1,2]. MRI also has superior diagnostic efficiency to CT in the detection of small (≤ 3cm) lesions[30]. However, CT is more readily available than MRI, and limitations to using MRI including greater costs and technical complexity make CT a complementary diagnostic alternative[31,32]. A report showed that the combined use of CT/MRI provides better diagnostic accuracy in characterizing liver lesions using LI-RADS (91.29%) than MRI (85.37%) or CT (67.6%) alone, but combined protocols should be limited to difficult or uncertain cases in order to warrant use[32].

***Contrast-enhanced ultrasound***

In recent years, there has been an emerging use of contrast-enhanced ultrasound (CEUS) for the evaluation of focal liver lesions (Figure 4). CEUS combines the benefit of accessible, non-invasive assessment without ionizing radiation as well as improvements in temporal resolution. Given some of the limitations in ultrasound sensitivity, CEUS may offer a useful solution. CEUS utilizes highly echogenic microbubble contrast agents (such as SonoVue®, Definity®) which are rapidly injected *via* the antecubital vein. These agents circulate freely among capillary beds, and the use of dynamic phases of contrast enhancement [*e.g.* arterial (start 10-20 s), portal (start 30-45 s), late (start > 120 s) phases] can help differentiate liver lesions[33].

The reporting system was initially developed for CT and MRI; however, in 2016, CEUS-LIRADS was released to improve standardization in reporting and interpretation specific to CEUS for nodule evaluation[33]. CEUS LI-RADS consists of 8 categories and ranges in greater levels of severity from LR-1 to LR-5, with additional categories such as LR-M (probably or definitely malignant but not HCC specific), LR-TIV, and LR-NC[33]. Diagnostic features of CEUS LI-RADS are based on arterial phase hyperenhancement and washout, or reductions in enhancement relative to the liver[33]. Features specific to HCC include arterial phase hypervascularity and late or low washout[34,35]. HCC displays earlier levels of enhancement compared to native liver tissue, and detection rates are greater for larger lesions (2-3 cm) compared to smaller ones (≤ 1 cm)[36]. Within nodules approximately 2 cm or greater, detection rates for ultrasound approach that of CT or MRI. For example, Gaiani *et al*[37] reported a detection rate of 91%-97.3% for evaluating hypervascularity in 103 cirrhotic nodules > 2 cm using CEUS[37]. Limitations of CEUS are like that of conventional ultrasound. Disadvantages of CEUS include user-dependent accuracy, the requirement for multiple contrast injections to survey or investigate separate liver lesions, and restricted ability to distinguish HCC from cholangiocarcinoma and stage disease[34,38].

**EMERGING ADVANCED IMAGING PROTOCOLS**

***CT and MR perfusion***

The acquisition of sequential imaging combined with IV contrast administration by multidetector can permit the assessment of tissue perfusion. The distribution of contrast media between the intravascular and interstitial compartments depends on the extent of blood flow and capillary permeability. Using kinetic modules, perfusion parameters across liver tissue can be calculated (blood flow, volume, permeability, hepatic arterial perfusion, portal venous perfusion, perfusion index, slope of increase/decrease). Quantitative color-graded perfusion maps can be used to localize lesions with abnormal tissue perfusion with a high degree of spatial resolution[39–42]. Tumor angiogenesis mediates differences in blood supply between normal liver parenchyma and HCC[42]. Quantitative parameters from CT perfusion, such as hepatic perfusion index, carries high sensitivity and specificity (≥ 99%) for HCC detection in patients with cirrhosis[43]. Early HCC lesions or hepatocellular nodules will demonstrate increased arterial supply as hepatocarcinogenesis progresses, reflected in increased hepatic arterial perfusion and perfusion indices[40]. Other common focal liver lesions can exhibit unique CT perfusion behavior and therefore be used to identify HCC from hemangiomas, liver metastases, and arterioportal shunts[44]. Bai *et al*[45] reported histopathological features such as microvascular density, a poor prognostic factor for HCC, is correlated with multiple perfusion parameters[45]. A major prognostic factor for HCC, microvascular density has been shown to be correlated with multiple CT perfusion parameters.

Similar to CT perfusion, dynamic contrast-enhanced MRI (DCE-MRI) permits the quantification of perfusion characteristics of liver lesions[46]. This approach is accomplished using gadolinium IV contrast administration followed by image acquisition with high temporal resolution and kinetic modules to quantify contrast distribution perfusion to reflect focal perfusion differences[47]. DCE-MRI perfusion parameters have highlighted unique physiological characteristics in HCC lesions, including increased arterial hepatic blood flow, arterial fraction, and lower portal hepatic blood flow, compared to normal liver parenchyma[46]. Pahwa *et al*[48] reported, arterial fraction and distribution volume are high in HCC and metastatic lesions compared to normal liver parenchyma[48]. Metastatic lesions may also be distinguished from HCC and normal liver parenchyma by the perfusion parameter mean transit time[48]. By evaluating tumor vascularity pre- and post-treatment, DCE-MRI has shown efficacy for treatment monitoring (*e.g.* following administration of anti-angiogenic agents, transarterial chemoembolization or radiotherapy) and predicting survival outcomes for HCC patients[49].

***Elastography***

Elastography is an imaging method to quantify mechanical properties, notably stiffness, to evaluate focal fibrotic cirrhotic changes (Figure 5). Either MRI or ultrasound, coupled with a device that generates low frequency vibrations (*i.e.* shear waves) and wave propagation, can be quantified in order to calculate levels of stiffness in a focal area of interest[50]. First introduced with ultrasound, there are multiple elastography methods which include transient elastography, point shear wave, two-dimensional sheer wave, and quasi-static elastography. Ultrasound elastography has shown to provide satisfactory sensitivity and specificity for identifying histological stages of severe fibrosis (sensitivity: 81.9%, specificity: 84.7%) and cirrhosis (sensitivity: 84.8%, specificity 87.5%)[51]. MRI elastography may also aid to differentiate focal liver lesions. For example, malignant tumors have been reported to have greater levels of stiffness relative to benign lesions, focal fibrotic regions, and normal liver parenchyma[52].

Evaluation of liver stiffness may also offer a prognostic biomarker for determining risk of HCC development and survival. A meta-analysis of 9 studies by Singh *et al*[53] reported increased liver stiffness is associated with an elevated risk of HCC[53]. A more recent metanalysis of 1735 patients reported a varied sensitivity (31%-100%) and high specificity (81%-94%) for predicting HCC development. The use of MR elastography can also be used as a biomarker to predict treatment response and tumor recurrence[54–56]. A prospective investigation assessed 192 patients undergoing HCC treatment (*e.g.* transarterial chemboembolization, ablation, or resection) found liver parenchymal stiffness to be an independent predictor of early recurrence[54]. A recent investigation also reported efficacy for predicting both early and late recurrence in 180 patients with HBV-related HCC prior to undergoing hepatectomy[56]. Qayyum *et al*[57] reported the use of MR elastography to evaluate stiffness changes in patients treated with immunotherapy (*i.e.* Pembrolizumab). HCC tumor stiffness significantly correlated with survival outcomes, including overall survival and time to disease progression, as well as intratumoral T-lymphocyte abundance[57].

***T1 mapping***

Similarly, T1 mapping is an MR method by which T1 relaxation time is measured and can be useful for identifying liver fibrosis. In the setting of inflammation and fibrosis, T1 relaxation time will be increased and has been used extensively to evaluate myocardial edema and scarring[58]. In fact, there is a moderate correlation between T1 relaxation time and elastography-measured stiffness[59]. T1 relaxation time can also be measured before and after administering hepatobiliary contrast agents such as GD-EOB-DTPA (Eovist®) to provide a more reliable, quantitative evaluation of contrast media uptake within the liver parenchyma[60]. Given that T1 relaxation is influenced by intrinsic properties of tissue, T1 mapping can overcome some of the traditional limitations of conventional MR signal intensity, which can be influenced by technical factors and imaging parameters. Combining T1 mapping and GD-EOB-DTPA has shown to be useful for identifying and classifying differentiated lesions (*e.g.* reduced uptake associated with increased HCC grade), and can be used to distinguish HCC from other focal liver lesions, including hepatic cysts, focal nodular hyperplasia, and hemangiomas[61–63]. HCCs with microvascular invasion have also shown reductions in T1 relaxation relative to lesions without evidence of microvascular invasion[64], showing promise of another imaging method for predicting prognosis.

***Diffusion weighted imaging***

Diffusion weighted imaging (DWI) is a non-invasive MR sequence which can characterize focal liver lesions without the need for contrast media by measuring diffusion properties of water molecules within tissues (Figure 6). Gradations of diffusion are measured using b-values, with greater values denoting more sensitivity to diffusion and higher signal intensity. These values are used to calculate and generate apparent diffusion coefficient (ADC) maps, used clinically to assess local changes in liver tissue diffusion[65]. Changes in cellularity, cell architecture and extracellular space, combined with necrosis and vascularization, can restrict diffusion and thus, HCC will appear hyperintense on DWI[65,66]. DWI has exhibited exceptionally high sensitivity and specificity for a single HCC lesion (100%) and moderate sensitivity and high specificity for multiple lesions (75% and 100%, respectively)[67]. The detection of early, smaller HCC (≤ 2 cm) is a clinically useful feature of DWI, especially when combined with contrast use. Generally, poorly differentiated lesions will exhibit lower ADC compared to well-differentiated lesions[66]. A meta-analysis of 21 studies (1799 HCC lesions) by Surov *et al*[68] reported that DWI can provide grading and prognostic utility by demonstrating use of ADC values can predict tumor grade and microvascular invasiveness (specifically, minimum ADC values)[68]. A recent study in 81 patients with HCC also reported microvascular invasiveness to be associated with ADC with a receiver operating characteristic curve AUC values ranging from 0.860-0.909[69]. DWI has been used as a biomarker for monitoring and predicting tumor response following locoregional therapy[70,71]. ADC correlates with tumor response, according to mRECIST, 6 mo after TACE[70]. ADC values of 1.84 × 10−3 mm2/s10 have been reported to have high sensitivity (92.3%) and specificity values (100%) for identifying evidence of necrosis following TACE[71]. For Y90-radioembolization, increases in ADC value (> 30%) can predict objective mRECIST response with 90% sensitivity and 100% specificity. Further, a > 30% change in ADC following TACE is associated with prolonged overall survival[72]. A prospective investigation of 40 patients treated with radiofrequency ablation found an ADC value of 1.01 × 10−3 mm2/s yields the highest sensitivity (80%) and specificity (100%) for detecting residual HCCs 3 mo following treatment[73]. However, differentiation between benign and malignant lesions are difficult in the setting of cirrhosis, as the ADC between both lesion types exhibit considerable overlap[65]. Further, standardization for DWI sequences may be needed since different study protocols can alter ADC calculation[74].

***MR spectroscopy***

MR spectroscopy is an analytical technique that permits the characterization and quantification of tissue metabolite composition in vivo. For each given voxel, a plot of signal intensity and metabolites/chemicals are expressed by their frequencies[75]. Malignant hepatic lesions have been found to have elevated choline levels relative to normal liver parenchyma. Changes in metabolite frequencies exist between healthy and cirrhotic livers, namely choline and lipid levels[76]. Choline is a component of phospholipid membranes, which increases in states of cell proliferation and carcinogenesis. Zhang *et al*[77] reported the diagnostic efficacy of measuring choline-containing compounds using MR spectroscopy is high for discriminating malignant and benign tumors (sensitivity: 94.3% and specificity: 93.3%)[77]. Determining ratios of choline and lipids within a given lesion has also been used to monitor treatment responses after locoregional therapy[78]. For example, prospective investigations have found choline levels to decline following TACE therapy[79,80].

***Radiogenomics/radiomics***

The integration of artificial intelligence and diagnostic imaging modalities has led to an exponential rise in radiogenomics or radiomics, which collectively refers to processes that aim to bridge quantitative radiologic data with immunobiological or clinical characteristics to inform prognosis or predict treatment outcomes[81]. The computing process consists of extracting quantitative features from medical images (CT, MRI or positron emission tomography) into large analyzable databases[82]. This process is carried out in multiple steps, including (1) defining volumes or regions of interest; (2) image segmentation (performed manually, semi-automatic or automatic tools); (3) image processing used to normalize grey-level intensities, denoise and improve data quality (*e.g.* signal intensity normalization, motion correction, filtering, image interpolation, and bias field correction); (4) feature extraction; and (5) statistical model building[83,84]. The final process, specific to oncology, includes generating association maps to correlate radiomic-based models with clinical outcome data, microvascular invasion, histological grade, or genomic/molecular data (*e.g.* immune marker expression).

Multiple studies have utilized either radiogenomic or radiomic models to diagnose and differentiate liver tumors or predict treatment efficacy for HCC[85–87]. For example, Lewis *et al*[88] reported greater prediction accuracy when combining LI-RADS and DWI-derived radiomics models using the ADC values than LI-RADS alone for distinguishing HCC from other primary liver cancers[88]. Banerjee *et al*[89] evaluated radiomic-models using contrast-enhanced CT to predict prognostic factors, such as microvascular invasion[89]. Radiogenomic venous invasion, an imaging biomarker, can predict microvascular invasion and correlates with lower overall and recurrence-free survival[89]. A recent meta-analysis/systematic review including 4947 patients showed promising predictive potential of radiomic models for microvascular invasion, reporting a pooled area under the curve (AUC) of 0.85, 0.87, and 0.74 across studies using CT, MR, and ultrasound-based models, respectively[90].

Given the link between gene expression and immunotherapy response, the ability to predict HCC immunoprofiles can be critical for delineating appropriate treatment. Hectors *et al*[91] retrospectively evaluated the relationship between MRI radiomic features (*e.g.* models using tumor size, enhancement ratios, fat content, ADC, texture features) and HCC immunhistochemical and genomic makers[91]. In particular, multiple relationships were found to exist between radiomic features and immunotherapy targets, cytotoxic T-lymphocyte-associated antigen 4 and programmed death 1[91]. Radiomic models have also shown promise for predicting treatment response and potential adverse outcomes after locoregional therapy use[92–96]. For example, MRI-based radiomics models have a reported AUC of 0.861 and 0.884 for predicting tumor response at 3-mo post TACE, evaluated using the mRECIST criterion. While larger, multi-center cohort models should be investigated in the future, the use of radiogenomics or radiomic models provide a novel method that can improve tumor grading, predicting prognosis and clinical decision-making strategies.

**CONCLUSION**

In summary, the use of imaging is an essential component to the diagnosis and management of HCC. Ultrasound is cost-effective modality for the screening. The utility of diagnostic modalities such as MR or CT for differentiation and grading of HCC continues to expand, especially with the advancement of new techniques and image analyses. The implementation of techniques, including elastography, T1 mapping, perfusion imaging and CEUS provide multiple unique benefits to further aid in the characterization of HCC. Other methods, such as radiomics/radiogenomics, which seek to integrate imaging data to predict prognostic risk factors and determine treatment response probability, will be a new frontier for informing clinical decision-making with the ultimate goal to generate more precise and personalized treatment management strategies for patients with HCC.

**REFERENCES**

1 **Villanueva A**. Hepatocellular Carcinoma. *N Engl J Med* 2019; **380**: 1450-1462 [PMID: 30970190 DOI: 10.1056/NEJMra1713263]

2 **Chakraborty E**, Sarkar D. Emerging Therapies for Hepatocellular Carcinoma (HCC). *Cancers (Basel)* 2022; **14** [PMID: 35681776 DOI: 10.3390/cancers14112798]

3 **Harris PS**, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: An evidence-based approach. *World J Gastroenterol* 2019; **25**: 1550-1559 [PMID: 30983815 DOI: 10.3748/wjg.v25.i13.1550]

4 **McGlynn KA**, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. *Hepatology* 2021; **73 Suppl 1**: 4-13 [PMID: 32319693 DOI: 10.1002/hep.31288]

5 **Parikh ND**, Tayob N, Al-Jarrah T, Kramer J, Melcher J, Smith D, Marquardt P, Liu PH, Tang R, Kanwal F, Singal AG. Barriers to Surveillance for Hepatocellular Carcinoma in a Multicenter Cohort. *JAMA Netw Open* 2022; **5**: e2223504 [PMID: 35867057 DOI: 10.1001/jamanetworkopen.2022.23504]

6 **Willatt J**, Ruma JA, Azar SF, Dasika NL, Syed F. Imaging of hepatocellular carcinoma and image guided therapies - how we do it. *Cancer Imaging* 2017; **17**: 9 [PMID: 28259177 DOI: 10.1186/s40644-017-0110-z]

7 **Marrero JA**, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology* 2018; **68**: 723-750 [PMID: 29624699 DOI: 10.1002/hep.29913]

8 **European Association for the Study of the Liver**. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol* 2018; **69**: 182-236 [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019]

9 **Omata M**, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. *Hepatol Int* 2017; **11**: 317-370 [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9]

10 **Ahn JC**, Lee YT, Agopian VG, Zhu Y, You S, Tseng HR, Yang JD. Hepatocellular carcinoma surveillance: current practice and future directions. *Hepatoma Res* 2022; **8** [PMID: 36161213 DOI: 10.20517/2394-5079.2021.131]

11 **Pocha C**, Dieperink E, McMaken KA, Knott A, Thuras P, Ho SB. Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography -- a randomised study. *Aliment Pharmacol Ther* 2013; **38**: 303-312 [PMID: 23750991 DOI: 10.1111/apt.12370]

12 **Zhang BH**, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. *J Cancer Res Clin Oncol* 2004; **130**: 417-422 [PMID: 15042359 DOI: 10.1007/s00432-004-0552-0]

13 **Morgan TA**, Maturen KE, Dahiya N, Sun MRM, Kamaya A; American College of Radiology Ultrasound Liver Imaging and Reporting Data System (US LI-RADS) Working Group. US LI-RADS: ultrasound liver imaging reporting and data system for screening and surveillance of hepatocellular carcinoma. *Abdom Radiol (NY)* 2018; **43**: 41-55 [PMID: 28936543 DOI: 10.1007/s00261-017-1317-y]

14 **Schoenberger H**, Chong N, Fetzer DT, Rich NE, Yokoo T, Khatri G, Olivares J, Parikh ND, Yopp AC, Marrero JA, Singal AG. Dynamic Changes in Ultrasound Quality for Hepatocellular Carcinoma Screening in Patients With Cirrhosis. *Clin Gastroenterol Hepatol* 2022; **20**: 1561-1569.e4 [PMID: 34119640 DOI: 10.1016/j.cgh.2021.06.012]

15 **Kim SY**, An J, Lim YS, Han S, Lee JY, Byun JH, Won HJ, Lee SJ, Lee HC, Lee YS. MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma. *JAMA Oncol* 2017; **3**: 456-463 [PMID: 27657493 DOI: 10.1001/jamaoncol.2016.3147]

16 **Tzartzeva K**, Singal AG. Testing for AFP in combination with ultrasound improves early liver cancer detection. *Expert Rev Gastroenterol Hepatol* 2018; **12**: 947-949 [PMID: 30118333 DOI: 10.1080/17474124.2018.1512855]

17 **Tzartzeva K**, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, Waljee AK, Singal AG. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. *Gastroenterology* 2018; **154**: 1706-1718.e1 [PMID: 29425931 DOI: 10.1053/j.gastro.2018.01.064]

18 **Yilmaz N,** Yilmaz UE, Suer K, Goral V, Cakir N. Screening for hepatocellular carcinoma: summary of current guidelines up to 2018. Hepatoma Research. 2018;4:46. DOI:10.20517/2394-5079.2018.49 [DOI:10.20517/2394-5079.2018.49]

19 **Choi DT**, Kum HC, Park S, Ohsfeldt RL, Shen Y, Parikh ND, Singal AG. Hepatocellular Carcinoma Screening Is Associated With Increased Survival of Patients With Cirrhosis. *Clin Gastroenterol Hepatol* 2019; **17**: 976-987.e4 [PMID: 30616961 DOI: 10.1016/j.cgh.2018.10.031]

20 **Beste LA**, Ioannou GN, Yang Y, Chang MF, Ross D, Dominitz JA. Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder. *Clin Gastroenterol Hepatol* 2015; **13**: 172-179 [PMID: 24813175 DOI: 10.1016/j.cgh.2014.04.033]

21 **Sherman M**. How to improve HCC surveillance outcomes. *JHEP Rep* 2019; **1**: 460-467 [PMID: 32039398 DOI: 10.1016/j.jhepr.2019.10.007]

22 **Kanmaniraja D**, Dellacerra G, Holder J, Erlichman D, Chernyak V. Liver Imaging Reporting and Data System (LI-RADS) v2018: Review of the CT/MRI Diagnostic Categories. *Can Assoc Radiol J* 2021; **72**: 142-149 [PMID: 32063008 DOI: 10.1177/0846537119888393]

23 **van der Pol CB**, Lim CS, Sirlin CB, McGrath TA, Salameh JP, Bashir MR, Tang A, Singal AG, Costa AF, Fowler K, McInnes MDF. Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy-A Systematic Review. *Gastroenterology* 2019; **156**: 976-986 [PMID: 30445016 DOI: 10.1053/j.gastro.2018.11.020]

24 **Kierans AS**, Song C, Gavlin A, Roudenko A, Lu L, Askin G, Hecht EM. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma. *AJR Am J Roentgenol* 2020; **215**: 1085-1092 [PMID: 32877248 DOI: 10.2214/AJR.20.22772]

25 **Choi JY**, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. *Radiology* 2014; **272**: 635-654 [PMID: 25153274 DOI: 10.1148/radiol.14132361]

26 **Kulkarni NM**, Fung A, Kambadakone AR, Yeh BM. Computed Tomography Techniques, Protocols, Advancements, and Future Directions in Liver Diseases. *Magn Reson Imaging Clin N Am* 2021; **29**: 305-320 [PMID: 34243919 DOI: 10.1016/j.mric.2021.05.002]

27 **Hope TA**, Fowler KJ, Sirlin CB, Costa EA, Yee J, Yeh BM, Heiken JP. Hepatobiliary agents and their role in LI-RADS. *Abdom Imaging* 2015; **40**: 613-625 [PMID: 25287679 DOI: 10.1007/s00261-014-0227-5]

28 **Niendorf E**, Spilseth B, Wang X, Taylor A. Contrast Enhanced MRI in the Diagnosis of HCC. *Diagnostics (Basel)* 2015; **5**: 383-398 [PMID: 26854161 DOI: 10.3390/diagnostics5030383]

29 **Schima W**, Heiken J. LI-RADS v2017 for liver nodules: how we read and report. *Cancer Imaging* 2018; **18**: 14 [PMID: 29690933 DOI: 10.1186/s40644-018-0149-5]

30 **Wang G**, Zhu S, Li X. Comparison of values of CT and MRI imaging in the diagnosis of hepatocellular carcinoma and analysis of prognostic factors. *Oncol Lett* 2019; **17**: 1184-1188 [PMID: 30655882 DOI: 10.3892/ol.2018.9690]

31 **Roberts LR**, Sirlin CB, Zaiem F, Almasri J, Prokop LJ, Heimbach JK, Murad MH, Mohammed K. Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. *Hepatology* 2018; **67**: 401-421 [PMID: 28859233 DOI: 10.1002/hep.29487]

32 **Basha MAA**, AlAzzazy MZ, Ahmed AF, Yousef HY, Shehata SM, El Sammak DAEA, Fathy T, Obaya AA, Abdelbary EH. Does a combined CT and MRI protocol enhance the diagnostic efficacy of LI-RADS in the categorization of hepatic observations? A prospective comparative study. *Eur Radiol* 2018; **28**: 2592-2603 [PMID: 29368164 DOI: 10.1007/s00330-017-5232-y]

33 **Bartolotta TV**, Terranova MC, Gagliardo C, Taibbi A. CEUS LI-RADS: a pictorial review. *Insights Imaging* 2020; **11**: 9 [PMID: 32020352 DOI: 10.1186/s13244-019-0819-2]

34 **Bartolotta TV**, Taibbi A, Midiri M, Lagalla R. Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand? *Ultrasonography* 2019; **38**: 200-214 [PMID: 31006227 DOI: 10.14366/usg.18060]

35 **D'Onofrio M**, Crosara S, De Robertis R, Canestrini S, Mucelli RP. Contrast-Enhanced Ultrasound of Focal Liver Lesions. *AJR Am J Roentgenol* 2015; **205**: W56-W66 [PMID: 26102419 DOI: 10.2214/AJR.14.14203]

36 **Zheng SG**, Xu HX, Liu LN. Management of hepatocellular carcinoma: The role of contrast-enhanced ultrasound. *World J Radiol* 2014; **6**: 7-14 [PMID: 24578787 DOI: 10.4329/wjr.v6.i1.7]

37 **Gaiani S**, Celli N, Piscaglia F, Cecilioni L, Losinno F, Giangregorio F, Mancini M, Pini P, Fornari F, Bolondi L. Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. *J Hepatol* 2004; **41**: 421-426 [PMID: 15336445 DOI: 10.1016/j.jhep.2004.04.022]

38 **Schwarze V**, Marschner C, Völckers W, Grosu S, Negrão de Figueiredo G, Rübenthaler J, Clevert DA. Diagnostic value of contrast-enhanced ultrasound versus computed tomography for hepatocellular carcinoma: a retrospective, single-center evaluation of 234 patients. *J Int Med Res* 2020; **48**: 300060520930151 [PMID: 32529869 DOI: 10.1177/0300060520930151]

39 **Navin PJ**, Venkatesh SK. Hepatocellular Carcinoma: State of the Art Imaging and Recent Advances. *J Clin Transl Hepatol* 2019; **7**: 72-85 [PMID: 30944823 DOI: 10.14218/JCTH.2018.00032]

40 **Kim SH**, Kamaya A, Willmann JK. CT perfusion of the liver: principles and applications in oncology. *Radiology* 2014; **272**: 322-344 [PMID: 25058132 DOI: 10.1148/radiol.14130091]

41 **Oğul H**, Kantarcı M, Genç B, Pirimoğlu B, Cullu N, Kızrak Y, Yılmaz O, Karabulut N. Perfusion CT imaging of the liver: review of clinical applications. *Diagn Interv Radiol* 2014; **20**: 379-389 [PMID: 24834487 DOI: 10.5152/dir.2014.13396]

42 **Nakamura Y**, Higaki T, Honda Y, Tatsugami F, Tani C, Fukumoto W, Narita K, Kondo S, Akagi M, Awai K. Advanced CT techniques for assessing hepatocellular carcinoma. *Radiol Med* 2021; **126**: 925-935 [PMID: 33954894 DOI: 10.1007/s11547-021-01366-4]

43 **Fischer MA**, Kartalis N, Grigoriadis A, Loizou L, Stål P, Leidner B, Aspelin P, Brismar TB. Perfusion computed tomography for detection of hepatocellular carcinoma in patients with liver cirrhosis. *Eur Radiol* 2015; **25**: 3123-3132 [PMID: 25903707 DOI: 10.1007/s00330-015-3732-1]

44 **Chartampilas E**, Rafailidis V, Georgopoulou V, Kalarakis G, Hatzidakis A, Prassopoulos P. Current Imaging Diagnosis of Hepatocellular Carcinoma. *Cancers (Basel)* 2022; **14** [PMID: 36010991 DOI: 10.3390/cancers14163997]

45 **Bai RJ**, Li JP, Ren SH, Jiang HJ, Liu XD, Ling ZS, Huang Q, Feng GL. A correlation of computed tomography perfusion and histopathology in tumor edges of hepatocellular carcinoma. *Hepatobiliary Pancreat Dis Int* 2014; **13**: 612-617 [PMID: 25475863 DOI: 10.1016/s1499-3872(14)60298-8]

46 **Taouli B**, Johnson RS, Hajdu CH, Oei MT, Merad M, Yee H, Rusinek H. Hepatocellular carcinoma: perfusion quantification with dynamic contrast-enhanced MRI. *AJR Am J Roentgenol* 2013; **201**: 795-800 [PMID: 24059368 DOI: 10.2214/AJR.12.9798]

47 **Aronhime S**, Calcagno C, Jajamovich GH, Dyvorne HA, Robson P, Dieterich D, Fiel MI, Martel-Laferriere V, Chatterji M, Rusinek H, Taouli B. DCE-MRI of the liver: effect of linear and nonlinear conversions on hepatic perfusion quantification and reproducibility. *J Magn Reson Imaging* 2014; **40**: 90-98 [PMID: 24923476 DOI: 10.1002/jmri.24341]

48 **Pahwa S**, Liu H, Chen Y, Dastmalchian S, O'Connor G, Lu Z, Badve C, Yu A, Wright K, Chalian H, Rao S, Fu C, Vallines I, Griswold M, Seiberlich N, Zeng M, Gulani V. Quantitative perfusion imaging of neoplastic liver lesions: A multi-institution study. *Sci Rep* 2018; **8**: 4990 [PMID: 29563601 DOI: 10.1038/s41598-018-20726-1]

49 **Chen BB**, Shih TT. DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker. *World J Gastroenterol* 2014; **20**: 3125-3134 [PMID: 24695624 DOI: 10.3748/wjg.v20.i12.3125]

50 **Guglielmo FF**, Venkatesh SK, Mitchell DG. Liver MR Elastography Technique and Image Interpretation: Pearls and Pitfalls. *Radiographics* 2019; **39**: 1983-2002 [PMID: 31626569 DOI: 10.1148/rg.2019190034]

51 **Malik P**, Pillai S, Agarwal K, Abdelwahed S, Bhandari R, Singh A, Chidharla A, Patel K, Singh P, Manaktala P, Rabbani R, Koritala T, Gupta S. Diagnostic Accuracy of Elastography and Liver Disease: A Meta-Analysis. *Gastroenterology Res* 2022; **15**: 232-239 [PMID: 36407808 DOI: 10.14740/gr1557]

52 **Venkatesh SK**, Yin M, Glockner JF, Takahashi N, Araoz PA, Talwalkar JA, Ehman RL. MR elastography of liver tumors: preliminary results. *AJR Am J Roentgenol* 2008; **190**: 1534-1540 [PMID: 18492904 DOI: 10.2214/AJR.07.3123]

53 **Singh S**, Fujii LL, Murad MH, Wang Z, Asrani SK, Ehman RL, Kamath PS, Talwalkar JA. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2013; **11**: 1573-84.e1-2; quiz e88-9 [PMID: 23954643 DOI: 10.1016/j.cgh.2013.07.034]

54 **Cho HJ**, Kim B, Kim HJ, Huh J, Kim JK, Lee JH, Seo CW, Ahn HR, Eun JW, Kim SS, Cho SW, Cheong JY. Liver stiffness measured by MR elastography is a predictor of early HCC recurrence after treatment. *Eur Radiol* 2020; **30**: 4182-4192 [PMID: 32189053 DOI: 10.1007/s00330-020-06792-y]

55 **Gordic S**, Ayache JB, Kennedy P, Besa C, Wagner M, Bane O, Ehman RL, Kim E, Taouli B. Value of tumor stiffness measured with MR elastography for assessment of response of hepatocellular carcinoma to locoregional therapy. *Abdom Radiol (NY)* 2017; **42**: 1685-1694 [PMID: 28154910 DOI: 10.1007/s00261-017-1066-y]

56 **Zhang L**, Chen J, Jiang H, Rong D, Guo N, Yang H, Zhu J, Hu B, He B, Yin M, Venkatesh SK, Ehman RL, Wang J. MR elastography as a biomarker for prediction of early and late recurrence in HBV-related hepatocellular carcinoma patients before hepatectomy. *Eur J Radiol* 2022; **152**: 110340 [PMID: 35580445 DOI: 10.1016/j.ejrad.2022.110340]

57 **Qayyum A**, Hwang KP, Stafford J, Verma A, Maru DM, Sandesh S, Sun J, Pestana RC, Avritscher R, Hassan MM, Amin H, Rashid A, Wistuba II, Ehman RL, Ma J, Kaseb AO. Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC. *J Immunother Cancer* 2019; **7**: 329 [PMID: 31779702 DOI: 10.1186/s40425-019-0766-y]

58 **Taylor AJ**, Salerno M, Dharmakumar R, Jerosch-Herold M. T1 Mapping: Basic Techniques and Clinical Applications. *JACC Cardiovasc Imaging* 2016; **9**: 67-81 [PMID: 26762877 DOI: 10.1016/j.jcmg.2015.11.005]

59 **Hoffman DH**, Ayoola A, Nickel D, Han F, Chandarana H, Shanbhogue KP. T1 mapping, T2 mapping and MR elastography of the liver for detection and staging of liver fibrosis. *Abdom Radiol (NY)* 2020; **45**: 692-700 [PMID: 31875241 DOI: 10.1007/s00261-019-02382-9]

60 **Katsube T**, Okada M, Kumano S, Hori M, Imaoka I, Ishii K, Kudo M, Kitagaki H, Murakami T. Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. *Invest Radiol* 2011; **46**: 277-283 [PMID: 21343827 DOI: 10.1097/RLI.0b013e318200f67d]

61 **Peng Z**, Jiang M, Cai H, Chan T, Dong Z, Luo Y, Li ZP, Feng ST. Gd-EOB-DTPA-enhanced magnetic resonance imaging combined with T1 mapping predicts the degree of differentiation in hepatocellular carcinoma. *BMC Cancer* 2016; **16**: 625 [PMID: 27520833 DOI: 10.1186/s12885-016-2607-4]

62 **Peng Z**, Li C, Chan T, Cai H, Luo Y, Dong Z, Li ZP, Feng ST. Quantitative evaluation of Gd-EOB-DTPA uptake in focal liver lesions by using T1 mapping: differences between hepatocellular carcinoma, hepatic focal nodular hyperplasia and cavernous hemangioma. *Oncotarget* 2017; **8**: 65435-65444 [PMID: 29029443 DOI: 10.18632/oncotarget.18918]

63 **Mio M**, Fujiwara Y, Tani K, Toyofuku T, Maeda T, Inoue T. Quantitative evaluation of focal liver lesions with T1 mapping using a phase-sensitive inversion recovery sequence on gadoxetic acid-enhanced MRI. *Eur J Radiol Open* 2021; **8**: 100312 [PMID: 33392362 DOI: 10.1016/j.ejro.2020.100312]

64 **Rao C**, Wang X, Li M, Zhou G, Gu H. Value of T1 mapping on gadoxetic acid-enhanced MRI for microvascular invasion of hepatocellular carcinoma: a retrospective study. *BMC Med Imaging* 2020; **20**: 43 [PMID: 32345247 DOI: 10.1186/s12880-020-00433-y]

65 **Kele PG**, van der Jagt EJ. Diffusion weighted imaging in the liver. *World J Gastroenterol* 2010; **16**: 1567-1576 [PMID: 20355235 DOI: 10.3748/wjg.v16.i13.1567]

66 **Saito K**, Tajima Y, Harada TL. Diffusion-weighted imaging of the liver: Current applications. *World J Radiol* 2016; **8**: 857-867 [PMID: 27928467 DOI: 10.4329/wjr.v8.i11.857]

67 **Shankar S**, Kalra N, Bhatia A, Srinivasan R, Singh P, Dhiman RK, Khandelwal N, Chawla Y. Role of Diffusion Weighted Imaging (DWI) for Hepatocellular Carcinoma (HCC) Detection and its Grading on 3T MRI: A Prospective Study. *J Clin Exp Hepatol* 2016; **6**: 303-310 [PMID: 28003720 DOI: 10.1016/j.jceh.2016.08.012]

68 **Surov A**, Pech M, Omari J, Fischbach F, Damm R, Fischbach K, Powerski M, Relja B, Wienke A. Diffusion-Weighted Imaging Reflects Tumor Grading and Microvascular Invasion in Hepatocellular Carcinoma. *Liver Cancer* 2021; **10**: 10-24 [PMID: 33708636 DOI: 10.1159/000511384]

69 **Jing M**, Cao Y, Zhang P, Zhang B, Lin X, Deng L, Han T, Zhou J. The Benefit of Apparent Diffusion Coefficient in Evaluating the Invasiveness of Hepatocellular Carcinoma. *Front Oncol* 2021; **11**: 719480 [PMID: 34504795 DOI: 10.3389/fonc.2021.719480]

70 **Ludwig JM**, Camacho JC, Kokabi N, Xing M, Kim HS. The Role of Diffusion-Weighted Imaging (DWI) in Locoregional Therapy Outcome Prediction and Response Assessment for Hepatocellular Carcinoma (HCC): The New Era of Functional Imaging Biomarkers. *Diagnostics (Basel)* 2015; **5**: 546-563 [PMID: 26854170 DOI: 10.3390/diagnostics5040546]

71 **Yuan Z**, Zhang J, Yang H, Ye XD, Xu LC, Li WT. Diffusion-Weighted MR Imaging of Hepatocellular Carcinoma: Current Value in Clinical Evaluation of Tumor Response to Locoregional Treatment. *J Vasc Interv Radiol* 2016; **27**: 20-30; quiz 31 [PMID: 26621785 DOI: 10.1016/j.jvir.2015.10.003]

72 **Kokabi N**, Camacho JC, Xing M, Qiu D, Kitajima H, Mittal PK, Kim HS. Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis. *Abdom Imaging* 2014; **39**: 969-978 [PMID: 24740759 DOI: 10.1007/s00261-014-0127-8]

73 **Elrefaey Hasan BM**, Abd ElHamid HAE, Khater NH, ElGendy W, Abdelrahman AS. Role of DWI in evaluation of HCC after radiofrequency ablation compared to dynamic MRI using MRI (3 T). *Egyptian J Radiol Nucl Med* 2021; **52**: 267 [DOI: 10.1186/s43055-021-00647-2]

74 **Granata V**, Fusco R, Filice S, Incollingo P, Belli A, Izzo F, Petrillo A. Comment on "State of the art in magnetic resonance imaging of hepatocellular carcinoma": the role of DWI. *Radiol Oncol* 2019; **53**: 369-370 [PMID: 31318697 DOI: 10.2478/raon-2019-0031]

75 **Qayyum A**. MR spectroscopy of the liver: principles and clinical applications. *Radiographics* 2009; **29**: 1653-1664 [PMID: 19959513 DOI: 10.1148/rg.296095520]

76 **Wang D**, Li Y. 1H Magnetic Resonance Spectroscopy Predicts Hepatocellular Carcinoma in a Subset of Patients With Liver Cirrhosis: A Randomized Trial. *Medicine (Baltimore)* 2015; **94**: e1066 [PMID: 26166077 DOI: 10.1097/MD.0000000000001066]

77 **Zhang L**, Zhao X, Ouyang H, Wang S, Zhou C. Diagnostic value of 3.0T (1)H MRS with choline-containing compounds ratio (∆CCC) in primary malignant hepatic tumors. *Cancer Imaging* 2016; **16**: 25 [PMID: 27549094 DOI: 10.1186/s40644-016-0082-4]

78 **Yang K**, Zhang XM, Yang L, Xu H, Peng J. Advanced imaging techniques in the therapeutic response of transarterial chemoembolization for hepatocellular carcinoma. *World J Gastroenterol* 2016; **22**: 4835-4847 [PMID: 27239110 DOI: 10.3748/wjg.v22.i20.4835]

79 **Kuo YT**, Li CW, Chen CY, Jao J, Wu DK, Liu GC. In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T MR scanner. *J Magn Reson Imaging* 2004; **19**: 598-604 [PMID: 15112309 DOI: 10.1002/jmri.20046]

80 **Chen CY**, Li CW, Kuo YT, Jaw TS, Wu DK, Jao JC, Hsu JS, Liu GC. Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants--initial experience. *Radiology* 2006; **239**: 448-456 [PMID: 16569781 DOI: 10.1148/radiol.2392042202]

81 **Jeong WK**, Jamshidi N, Felker ER, Raman SS, Lu DS. Radiomics and radiogenomics of primary liver cancers. *Clin Mol Hepatol* 2019; **25**: 21-29 [PMID: 30441889 DOI: 10.3350/cmh.2018.1007]

82 **Gillies RJ**, Kinahan PE, Hricak H. Radiomics: Images Are More than Pictures, They Are Data. *Radiology* 2016; **278**: 563-577 [PMID: 26579733 DOI: 10.1148/radiol.2015151169]

83 **Shur JD**, Doran SJ, Kumar S, Ap Dafydd D, Downey K, O'Connor JPB, Papanikolaou N, Messiou C, Koh DM, Orton MR. Radiomics in Oncology: A Practical Guide. *Radiographics* 2021; **41**: 1717-1732 [PMID: 34597235 DOI: 10.1148/rg.2021210037]

84 **van Timmeren JE**, Cester D, Tanadini-Lang S, Alkadhi H, Baessler B. Radiomics in medical imaging-"how-to" guide and critical reflection. *Insights Imaging* 2020; **11**: 91 [PMID: 32785796 DOI: 10.1186/s13244-020-00887-2]

85 **Gong XQ**, Tao YY, Wu YK, Liu N, Yu X, Wang R, Zheng J, Liu N, Huang XH, Li JD, Yang G, Wei XQ, Yang L, Zhang XM. Progress of MRI Radiomics in Hepatocellular Carcinoma. *Front Oncol* 2021; **11**: 698373 [PMID: 34616673 DOI: 10.3389/fonc.2021.698373]

86 **Fu J,** Cao SJ, Song L, Tong XQ, Wang J, Yang M, Zou YH. Radiomics/Radiogenomics in hepatocellular carcinoma: Applications and challenges in interventional management. *iLIVER* 2022; **1**: 96-100 [DOI: 10.1016/j.iliver.2022.07.001]

87 **Yao S**, Ye Z, Wei Y, Jiang HY, Song B. Radiomics in hepatocellular carcinoma: A state-of-the-art review. *World J Gastrointest Oncol* 2021; **13**: 1599-1615 [PMID: 34853638 DOI: 10.4251/wjgo.v13.i11.1599]

88 **Lewis S**, Peti S, Hectors SJ, King M, Rosen A, Kamath A, Putra J, Thung S, Taouli B. Volumetric quantitative histogram analysis using diffusion-weighted magnetic resonance imaging to differentiate HCC from other primary liver cancers. *Abdom Radiol (NY)* 2019; **44**: 912-922 [PMID: 30712136 DOI: 10.1007/s00261-019-01906-7]

89 **Banerjee S**, Wang DS, Kim HJ, Sirlin CB, Chan MG, Korn RL, Rutman AM, Siripongsakun S, Lu D, Imanbayev G, Kuo MD. A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma. *Hepatology* 2015; **62**: 792-800 [PMID: 25930992 DOI: 10.1002/hep.27877]

90 **Zhong X**, Long H, Su L, Zheng R, Wang W, Duan Y, Hu H, Lin M, Xie X. Radiomics models for preoperative prediction of microvascular invasion in hepatocellular carcinoma: a systematic review and meta-analysis. *Abdom Radiol (NY)* 2022; **47**: 2071-2088 [PMID: 35364684 DOI: 10.1007/s00261-022-03496-3]

91 **Hectors SJ**, Lewis S, Besa C, King MJ, Said D, Putra J, Ward S, Higashi T, Thung S, Yao S, Laface I, Schwartz M, Gnjatic S, Merad M, Hoshida Y, Taouli B. MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. *Eur Radiol* 2020; **30**: 3759-3769 [PMID: 32086577 DOI: 10.1007/s00330-020-06675-2]

92 **Niu XK**, He XF. Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma. *World J Gastroenterol* 2021; **27**: 189-207 [PMID: 33510559 DOI: 10.3748/wjg.v27.i2.189]

93 **Kong C**, Zhao Z, Chen W, Lv X, Shu G, Ye M, Song J, Ying X, Weng Q, Weng W, Fang S, Chen M, Tu J, Ji J. Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE. *Eur Radiol* 2021; **31**: 7500-7511 [PMID: 33860832 DOI: 10.1007/s00330-021-07910-0]

94 **Sheen H**, Kim JS, Lee JK, Choi SY, Baek SY, Kim JY. A radiomics nomogram for predicting transcatheter arterial chemoembolization refractoriness of hepatocellular carcinoma without extrahepatic metastasis or macrovascular invasion. *Abdom Radiol (NY)* 2021; **46**: 2839-2849 [PMID: 33388805 DOI: 10.1007/s00261-020-02884-x]

95 **Bai H**, Meng S, Xiong C, Liu Z, Shi W, Ren Q, Xia W, Zhao X, Jian J, Song Y, Ni C, Gao X, Li Z. Preoperative CECT-based Radiomic Signature for Predicting the Response of Transarterial Chemoembolization (TACE) Therapy in Hepatocellular Carcinoma. *Cardiovasc Intervent Radiol* 2022; **45**: 1524-1533 [PMID: 35896687 DOI: 10.1007/s00270-022-03221-z]

96 **Zhao Y**, Wang N, Wu J, Zhang Q, Lin T, Yao Y, Chen Z, Wang M, Sheng L, Liu J, Song Q, Wang F, An X, Guo Y, Li X, Wu T, Liu AL. Radiomics Analysis Based on Contrast-Enhanced MRI for Prediction of Therapeutic Response to Transarterial Chemoembolization in Hepatocellular Carcinoma. *Front Oncol* 2021; **11**: 582788 [PMID: 33868988 DOI: 10.3389/fonc.2021.582788]

**Footnotes**

**Conflict-of-interest statement:** All theauthors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 18, 2022

**First decision:** January 31, 2023

**Article in press:** March 22, 2023

**Specialty type:** Radiology, nuclear medicine and medical imaging

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0


**P-Reviewer:** Kumar SKY, India; Papadopoulos N, Greece **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Fan JR

**Figure Legends**

图片包含 桌子, 照片, 黑暗, 猫

描述已自动生成

**Figure 1 Screening ultrasound.** Hyperechoic segment IV liver lesion compatible and later characterized as hepatocellular carcinoma.




**Figure 2 Axial multiphasic computed tomography imaging 75-year-old male with suspected hepatocellular carcinoma.** A: Hyperenhancing liver lesion in segment VIII during the arterial phase; B: Corresponding washout within the delayed venous phase.


图片包含 照片, 不同, 桌子, 食物

描述已自动生成


**Figure 3 Axial multiphasic magnetic resonance imaging.** A: T2-weighted axial sequence imaging of the abdomen; B: T1-weighted fat saturation post-contrast axial sequence image of the abdomen with arterial enhancement of segment VIII lesion; C: Delayed venous phase washout.



**Figure 4 Contrast-enhanced ultrasound.** A: 62-year-old female with lesion in segment III with hepatocellular carcinoma; B: Gray-scale conventional ultrasound; C: Contrast-enhanced ultrasound revealing hyperechoic lesion in arterial phase with corresponding washout in venous phase.



**Figure 5 Magnetic resonance imaging elastography of the liver.** Resoundant driver system was used to induce acoustic vibrations in the liver, which were then tracked using magnetic resonance imaging (MRI) scanner to estimate hepatic stiffness. Gray scale and color-scale MRI elastography stiffness sequence. The mean liver stiffness is 4.0 kPa (range: 3.8-4.2 kPa). < 2.5 kPa = Normal; 0.5 to 2.93 kPa = Normal or inflammation; 2.93-3.5 kPa = Stage 1-2 fibrosis; 3.5-4 kPa = Stage 2-3 fibrosis; 4-5 kPa = Stage 3-4 fibrosis; > 5 kPa = Stage 4 or cirrhosis. A: Gray scale; B: Color-scale.



**Figure 6 Diffusion-weighted imaging.** A: Diffusion-weighted imaging sequence; B: Apparent diffusion coefficient (ADC) map. Increased signal can be observed within the segment VIII lesion with corresponding hypointensity on ADC map, compatible with diffusion restriction.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**